# A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

> **NCT03227471** · PHASE1,PHASE2 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 225 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** IVA
- **DRUG:** TEZ/IVA
- **DRUG:** VX-445
- **DRUG:** Matched Placebo
- **DRUG:** TEZ
- **DRUG:** VX-561
- **DRUG:** VX-445

## Key facts

- **NCT ID:** NCT03227471
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-23
- **Primary completion:** 2018-03-27
- **Final completion:** 2018-03-27
- **Target enrollment:** 225 (ACTUAL)
- **Last updated:** 2022-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03227471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03227471, "A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03227471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*